The Glomerulonephritis drugs in development market research report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Glomerulonephritis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued products.
GlobalData tracks 120 drugs in development for Glomerulonephritis by 89 companies/universities/institutes. The top development phase for Glomerulonephritis is preclinical with 42 drugs in that stage. The Glomerulonephritis pipeline has 115 drugs in development by companies and five by universities/ institutes. Some of the companies in the Glomerulonephritis pipeline products market are: NovelMed Therapeutics, Jiangsu Hengrui Medicine and Omeros.
The key targets in the Glomerulonephritis pipeline products market include Mannan Binding Lectin Serine Protease 2, Complement Factor B, and Tumor Necrosis Factor Ligand Superfamily Member 13.
The key mechanisms of action in the Glomerulonephritis pipeline product include Mannan Binding Lectin Serine Protease 2 Inhibitor with nine drugs in Phase II. The Glomerulonephritis pipeline products include nine routes of administration with the top ROA being Oral and 14 key molecule types in the Glomerulonephritis pipeline products market including Small Molecule, and Monoclonal Antibody.
Glomerulonephritis overview
Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat (strep throat), immune diseases such as lupus, type 1 and type 2 diabetes, and viral infections such as HIV, hepatitis B virus, and hepatitis C virus. Risk factors include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis, and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, and welling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis and can include medications, lifestyle changes, dialysis, and transplant.
For a complete picture of Glomerulonephritis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
